Nervius (Pramipexole Dihydrochloride Monohydrate)

Pramipexole Dihydrochloride Monohydrate, the active ingredient in Nervius, is a dopamine agonist presented as an oral dosage form for oral use. It is employed to manage motor symptoms in Parkinson's disease and to alleviate symptoms of Restless Legs Syndrome in adult patients.

GNH USA supplies Nervius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pramipexole acts on dopaminergic pathways to treat movement disorders and related conditions. - Parkinson's disease: improves motor control and reduces rigidity and tremor. - Restless Legs Syndrome: decreases the urge to move the legs and improves sleep quality. - Motor fluctuations in Parkinson's disease: lessens "off" periods and stabilises symptom control.

Pramipexole may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness, especially when standing. - Somnolence: increased sleepiness during the day. - Constipation: reduced bowel movements. - Headache: mild to moderate head pain. - Hallucinations: visual or auditory disturbances, more common in older patients.

Serious or Rare Side Effects: - Impulse control disorders: compulsive gambling, shopping, or eating. - Orthostatic hypotension: sudden drop in blood pressure upon standing. - Sudden onset of sleep: unexpected sleep episodes. - Depression or suicidal thoughts: mood changes requiring immediate attention. - Severe allergic reactions: rash, swelling, or breathing difficulty. - Psychosis: severe confusion or delusional thinking.

Before initiating therapy with Nervius, consider the following safety measures. - Renal impairment: adjust dose based on kidney function. - Elderly patients: monitor for excessive sedation and falls. - History of psychiatric disorders: use with caution due to risk of hallucinations or mood changes. - Concomitant MAO‑inhibitors: avoid concurrent use to prevent hypertensive reactions. - Pregnancy and breastfeeding: safety not established; weigh potential benefits against risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pramipexole may interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - MAO‑inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Antipsychotics that block dopamine receptors: may diminish pramipexole’s effect. - Strong CYP2D6 inhibitors (e.g., quinidine): can raise pramipexole plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure‑lowering effect. - Alcohol: may enhance sedation and dizziness. - Other dopamine agonists: increase likelihood of impulse‑control problems.